Trials / Recruiting
RecruitingNCT07158918
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- ABL Bio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABL103 | IV infusion |
| DRUG | KEYTRUDA® (pembrolizumab) | IV infusion |
| DRUG | Taxane | IV infusion |
Timeline
- Start date
- 2025-08-06
- Primary completion
- 2027-12-02
- Completion
- 2027-12-02
- First posted
- 2025-09-08
- Last updated
- 2025-09-08
Locations
6 sites across 3 countries: United States, Australia, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07158918. Inclusion in this directory is not an endorsement.